Merck KGaA Breaks Ground for New Pharma Facility in China
Merck KGaAÂ´s biopharmaceuticals division has broken ground for its new pharmaceutical manufacturing facility in Nantong, China. The new facility, which will be the company’s second-largest pharmaceutical manufacturing facility worldwide, will focus on the bulk production and packaging of Glucophage (metformin hydrochloride), Concor (bisoprolol) and Euthyrox (levothyroxine sodium), Merck KGaAÂ´s brands for the treatment of diabetes, cardiovascular diseases, and thyroid disorders, respectively.
The new pharmaceutical manufacturing plant is located in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area). Based in NETDA's BioSpark zone, a high-tech industrial park designed to accommodate life science enterprises, the plant represents an investment of EUR 80 million ($105 million) and will be Merck's largest manufacturing facility outside of Europe. The new facility will cover an area of 40,000 square meters, with a possible 20,000-square meters extension. The construction of the site is scheduled to be completed in 2016, with commercial production starting in 2017.
Source: Merck KGaA